Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2007 | 12-2006 | 09-2006 | 06-2006 | 03-2006 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 70,971 | 44,189 | 16,101 | 15,100 | 17,571 |
| Receivables | 553 | 364 | 384 | 401 | 120 |
| Inventories | 475 | 443 | 234 | 414 | 286 |
| TOTAL | $73,295 | $45,594 | $17,332 | $16,454 | $18,582 |
| Non-Current Assets | |||||
| PPE Net | 572 | 498 | 461 | 369 | 367 |
| Other Non-Current Assets | 0 | 0 | 19 | 19 | 23 |
| TOTAL | $572 | $498 | $480 | $388 | $390 |
| Total Assets | $73,867 | $46,091 | $17,812 | $16,842 | $18,972 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,072 | 2,017 | 1,428 | 1,106 | 1,621 |
| Accrued Expenses | 1,187 | 1,011 | 1,207 | 928 | 818 |
| TOTAL | $5,156 | $4,251 | $2,757 | $2,426 | $2,693 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 2,897 | 1,222 | 122 | 391 | 254 |
| TOTAL | $27,807 | $18,760 | $N/A | $N/A | $N/A |
| Total Liabilities | $32,963 | $23,010 | $2,757 | $2,426 | $2,693 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 71,944 | 71,042 | 64,449 | 62,064 | 61,749 |
| Common Shares | 72 | 69 | 64 | 62 | 61 |
| Retained earnings | -44,457 | -41,099 | -36,721 | -33,070 | -29,838 |
| TOTAL | $40,904 | $23,081 | $15,055 | $14,416 | $16,278 |
| Total Liabilities And Equity | $73,867 | $46,091 | $17,812 | $16,842 | $18,972 |